Amphastar Pharmaceuticals (AMPH) reported $183.9 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 5.4%. EPS of $0.91 for the same period compares to $0.85 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $181.94 million, representing a surprise of +1.08%. The company delivered an EPS surprise of +37.88%, with the consensus EPS estimate being $0.66.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Amphastar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net revenues- Primatene MIST: $21 million versus $27.45 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -8.2% change.
  • Net revenues- Epinephrine: $15.85 million versus the two-analyst average estimate of $16.53 million. The reported number represents a year-over-year change of -2%.
  • Net revenues- BAQSIMI: $45.5 million compared to the $43.68 million average estimate based on two analysts. The reported number represents a change of -2.5% year over year.
  • Net revenues- Glucagon: $11.91 million versus $8.01 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -42.2% change.
  • Net revenues- Lidocaine: $15.04 million versus the two-analyst average estimate of $12.91 million. The reported number represents a year-over-year change of +0.3%.

View all Key Company Metrics for Amphastar here>>>

Shares of Amphastar have returned +7.2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Amphastar Pharmaceuticals, Inc. (AMPH): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research